ALT5 Sigma Corp.
ALTS
Market Cap$29.42M
Close$
$0.91
91.1% downside
Current Fair Value
91.1% downsideOvervalued by 91.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $29.42 Million |
|---|---|
| Enterprise Value | $35.68 Million |
| Dividend Yield | $0 (-%) |
| Earnings per Share | $- |
| Beta | 2.21 |
| Outstanding Shares | - |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2.85 |
| Enterprise Value to EBIT | -4.19 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.38 |
| Debt to Equity | 0.64 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About BioAge Labs, Inc.
62 employees
CEO: Dr. Kristen Fortney Ph.D. BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets bas...